Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 9/20 | 0.65 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.65 |
| ▸ | PDE4A | P27815 | 10/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19447761 | 0.91 | PDE1A (0.66) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL17508443 | 0.90 | PDE1A (0.79) | PDE1APDE1BPDE4A | |
| SCHEMBL17508439 | 0.90 | PDE1A (0.64) | PDE1APDE1BPDE4A | |
| SCHEMBL19447765 | 0.84 | PDE1A (0.64) | PDE1APDE1BPDE4A | |
| SCHEMBL17610009 | 0.84 | PDE1A (0.77) | PDE1APDE1BPDE4A | |
| SCHEMBL17508449 | 0.83 | PDE1A (0.72) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL19447762 | 0.82 | PDE1A (0.66) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL17610016 | 0.82 | PDE1A (0.79) | PDE1APDE1BPDE4A | |
| SCHEMBL14158337 | 0.80 | PDE1A (0.80) | PDE1APDE1BPDE4A | |
| SCHEMBL17508441 | 0.80 | PDE1A (0.79) | PDE1APDE1BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177627-B1 | IMIDAZO[1,2-A]-PYRAZOLO[4,3-E]-PYRIMIDIN-4-ONE DERIVATIVES WITH PDE1 INHIBITING ACTIVITY | INTRA CELLULAR THERAPIES INC (US) | 2019-07-24 | — | — | EP | claimed |
| EP-3177627-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2017-06-14 | — | — | EP | claimed |
| WO-2016022893-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-11 | — | — | WO | claimed |
| EP-3177627-B1 | IMIDAZO[1,2-A]-PYRAZOLO[4,3-E]-PYRIMIDIN-4-ONE DERIVATIVES WITH PDE1 INHIBITING ACTIVITY | INTRA CELLULAR THERAPIES INC (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20170226117-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226117-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2017-08-10 | — | — | US | disclosed |
| EP-3177627-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016022893-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016022893-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226117-A1 | ORGANIC COMPOUNDS | PRKG1, PDE2A, PDE3B | PDE1A 107/4885PDE1B 114/4885PDE4A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.